Technical Transfer of manufacturing process to CMO signals commencement of commercial readiness activities NDA planned for Q4 2019 FREMONT, Calif. , June 18, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has
Multiple catalysts, including Qtrypta TM NDA submission, anticipated in 2019 Company bolstered balance sheet to advance proprietary programs and expand applicability of ADAM microneedle technology Conference call scheduled for 1:30 pm PT today FREMONT, Calif.
FREMONT, Calif. , May 09, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has issued and sold an additional 750,000 shares of common stock, pursuant to the exercise in full of the underwriter’s option to purchase
FREMONT, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Tuesday, May 14, 2019 at 4:30 p.m. ET to discuss results for the first quarter of 2019 and
FREMONT, Calif. , April 16, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the peer-reviewed publication of a review and analysis of recently-completed trials using newly FDA -recommended
FREMONT, Calif. , April 09, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of its common stock for gross proceeds of $17.5 million , before deducting underwriting discounts
FREMONT, Calif. , April 08, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered
FREMONT, Calif. --(BUSINESS WIRE)--Mar. 14, 2019-- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2018 , as well as recent business highlights.
FREMONT, Calif. , March 11, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John Walker , will participate in a panel titled “Drug Delivery” to be held on Monday,
FREMONT, Calif. , March 07, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Thursday, March 14, 2019 at 4:30 p.m. ET to discuss financial results for the fourth quarter
